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Jan Øystein Berle1*, Else-Marie Løberg1,2 and Ole Bernt Fasmer1,3,4Abstract
Background: In patients with schizophrenia, altered brain activation and motor activity levels are central features,
reflecting cognitive impairments and negative symptoms, respectively. Newer studies using nonlinear methods
have addressed the severe disturbances in neurocognitive functioning that is regarded as one of the core features
of schizophrenia. Our aim was to compare brain activation and motor activity in a patient during pharmacological
treatment that was switched from a first- to a second-generation antipsychotic drug. We hypothesised that this
change of medication would increase level of responding in both measures.
Case presentation: We present the case of a 53-year-old male with onset of severe mental illness in adolescence,
ICD-10 diagnosed as schizophrenia of paranoid type, chronic form. We compared brain activation and motor
activity in this patient during pharmacological treatment with a first-generation (perphenazin), and later switched to
a second-generation (risperidone) antipsychotic drug. We used functional magnetic resonance imaging (fMRI) to
measure brain activation and wrist worn actigraphy to measure motor activity.
Conclusion: Our study showed that brain activation decreased in areas critical for cognitive functioning in this
patient, when changing from a first to a second generation antipsychotic drug. However the mean motor activity
level was unchanged, although risperidone reduced variability, particularly short-term variability from minute to
minute. Compared to the results from previous studies, the present findings indicate that changing to a second-
generation antipsychotic alters variability measures towards that seen in a control group, but with reduced brain
activation, which was an unexpected finding.
Keywords: Schizophrenia, Antipsychotic, Brain activation, fMRI, Neurocognitive, Motor activityBackground
Altered brain activation and reduced motor activity
levels are central features of schizophrenia. Altered
brain activation has often been reported in frontal re-
gions during cognitive demanding tasks [1,2]. The term
hypofrontality has been used by several authors to define
this effect, which also has been seen in first-episode
patients with schizophrenia [2] and neuroleptic-naive
patients [1]. Recent studies present however a more
complex picture, including for instance compensatory* Correspondence: jaob@helse-bergen.no
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reproduction in any medium, provided the orincreased activation in other brain regions [1], altered
brain activation in schizophrenia is seen as a reflection
of the cognitive impairments in this patient group [2].
Cognitive impairments with clinical consequences are
seen in a majority of patients with schizophrenia [3,4].
Reduced motor activity is one of several negative
symptoms in schizophrenia. Motor retardation can be
described as a reduction in motor activity as reflected in
slowing or retardation of movements and speech, and
reduced body tone. In addition, side-effects of the motor
type are commonly reported when treating these disorders
with antipsychotic medication [5], particularly when using
first generation antipsychotics (FGA). Furthermore, ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Mental arithmetic task: 
”Add two and two 
consecutive numbers and 
press the button 
whenever the sum is 10” 
(_ under a number 
indicates that is a target 
stimulus)
Figure 1 Task performed during the fMRI recordings.
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in schizophrenia has been reported [6]. Both cognitive
impairments and negative symptoms have been shown to
be important prognostic predictors in schizophrenia,
predicting functional outcome better than positive symp-
toms [3,7].
It would be of clinical importance if there was a differ-
ence between a first-generation antipsychotic (FGA) and
a second-generation antipsychotic (SGA) drug with
regard to brain activation and motor activity. SGAs are
hypothesized as having a more beneficial influence on
the negative symptoms than the older (FGA) antipsy-
chotics. The SGAs also have different pharmacological
profiles with regard to brain regions involved in cogni-
tion and movement.
Thus, although functional neuroimaging traditionally
is a research tool, studies of brain activation and motor
activity may also have clinical consequences, on an indi-
vidual level where there is a need for objective measures.
The brain imaging method fMRI is a technique that al-
lows detection of the brain areas that are involved in the
performance of a cognitive or emotional task. We chose
an arithmetic task with working memory load as the
stimulus, or task, paradigm to tap cognitive processes at-
tributed to frontal brain areas and brain areas rich in
dopaminergic receptors [8], which could reflect effects
of medication. The task was similar to the experimental
design used by Hugdahl et al. [9].
Assessment of motor activity in psychiatry is seldom
done using objective methods, in contrast to for example
in neurology. In our study motor activity was monitored
by a wrist worn actigraph. Actigraphy is an objective
method to register accumulated motor activity over time
for later analysis of movement frequency and amplitude.
In schizophrenia, actigraphy has been used to investigate
activity levels and circadian rest-activity phases and
motor activity pattern [10,11].
The aim of our study was to explore putative changes
in brain activation and in motor activity in a patient with
schizophrenia during antipsychotic treatment with the
FGA perphenazine and after switching to the SGA ris-
peridone. We hypothesised that this change of medica-
tion would increase brain activation and motor activity.
Case presentation
The patient
The patients was male, Caucasian, and 53 years old.
There were numerous incidences of severe mental illness
in his family. His intellectual level was within the normal
range; basic education, but no training or education as
skilled worker or to a higher level. He had no significant
somatic illness nor brain damage or other injuries. His
alcohol consumption was within acceptable levels in the
population and no use of illegal drugs was reported. Thispatient had symptom onset of severe mental illness in
young adulthood; paranoid psychotic symptoms, auditory
hallucinations, episodes with aggressive behaviour, dysfunc-
tion in activities of daily living. He was diagnosed with
schizophrenia, paranoid type, chronic form, chronic phase
(F20.0 in the ICD-10), although in periods affective symp-
toms of depression were present as well.
Methods
In the first registration period the patient was treated
with perphenazine decanoate 216 mg im/14th day, and
in addition received chlorprotixene 100 mg and valpro-
ate 1200 mg daily. Drug monitoring revealed a trough
serum level of perphenazine of 22 nmol/L, well above
the recommended reference range of 1 to 6 nmol/L.
Serum valproate was 467 nmol/L.
In the second registration period the antipsychotic
medication was switched into risperidone (Risperdal
Consta®), a long-acting intramuscular formulation. Drug
monitoring of risperidone (s-risperidone + 9-OH risperi-
done) revealed a trough serum level of 114 nmol/L,
serum level within the recommended reference range.
Genotyping revealed that the patient was a CYP2D6
slow metabolizer (CYP2D6*4/CYP2D6*4).
The fMRI image acquisitions were done both during
treatment with FGA, and again at follow-up ~6 months
after the patient had been switched to a SGA. Cognitive
function was examined using a mental arithmetic and
working memory task where the patient had to add two-
and-two successive numbers presented visually in LCD
goggles, and press a response button placed on the chest
whenever the sum of the numbers seen in the goggles
was 10 [Figure 1]. fMRI was performed with a 1.5 T
Siemens Vision Plus scanner equipped with 25 mT/m
gradients. Initial scanning of anatomy was done with a
T1W 3D FLASH pulse sequence. Thereafter, serial
imaging with 100 BOLD sensitive echo planar (EPI pulse
sequence) whole brain measurements were done during
the task. Each EPI volume measurement consisted of 40
axial slices which constituted an image volume (FA/TA/
TE/FOV/matrix = 500/6 s/84 ms/230 mm/64×64). The
in-plane pixel size was 3.44 × 3.44 mm, each slice with a
thickness of 3.0 mm, thus creating nearly isotropic
voxels. The first 10 image volumes were discarded prior
to statistical analyses, to avoid artifacts due to stimulus
novelty.
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formance, presented in a box-car design. The digit stim-
uli were the numbers “1” through “9”. There were 16
trials with digit stimuli presented during each ON block,
thus the total number of trials was 48. Each digit stimu-
lus was presented for 300 ms, with 2200 ms blank
interstimulus intervals (ISIs) in between. Thus, the total
ON blocks lasted 120 sec, with a total of 60 sec OFF
blocks. The ON and OFF blocks were alternated within
the run. The digit stimuli were presented with the Micro
Electronic Laboratory (MEL2) software (Psychology Soft-
ware Tools Inc.). The OFF blocks consisted of resting with
no stimulus presentations. The patient viewed the digit
stimuli in electronic goggles consisting of a LCD-screen
(Magnetic Resonance Technology Inc.) that were
connected to a PC outside the MR chamber, which
contained the MEL software. A response button was placed
on the participant’s chest that he was instructed to press
according to the specific instructions for each run. The pa-
tient was instructed to “add each consecutive number seen
in the goggles to the previous one, and press the button
whenever the sum was 10”. There were 6 presentations
where the sum was “10” among the 16 trials for each ON
block. Thus, the total number of target presentations,
across the three ON blocks, were 18. The fMRI set-up was
repeated twice in two separate sessions, with the different
medications, respectively.
The fMRI images were statistically analyzed using
the SPM5 software (http://www.fil.ion.ucl.ac.uk/spm).
The data were first pre-processed, including realigning
images, smoothing (8 mm) and normalizing to the
standard MNI template and co-ordinate system, and
then subjected to significance testing with t-tests.
Motor activity was monitored with an actigraph worn at
the right wrist (Actiwatch, Cambridge Neurotechnology
Ltd, England). The right wrist was chosen for the conveni-
ence of the participant. Previous studies have shown small
differences between the right and left wrist. Total activity
counts were recorded during one minute intervals. Motor
activity was monitored on a 24 hour basis during two sep-
arate two week periods 6 months apart performed when
the patient was on FGA (perphenazine), and later after
switching to SGA (risperidone). The fMRI were performed
in close proximity to these two periods.
Both medications were given as intramuscular depot
injections to ensure adherence to treatment, and thera-
peutic drug monitoring (TDM) were performed on both
medications to ensure adequate dosage. All samples
were analyzed by a LC/MSD method. Genotyping of
CYP2D6 was also performed to evaluate the patient’s
metabolic capacity.
Average activity per minute, the standard deviation (SD),
the root mean square successive differences (RMSSD), the
relation between RMSSD and SD (RMSSD/SD), andsample entropy were calculated for one continuous activity
period each day, defined as the longest period containing
not more than 9 consecutive minutes with zero activity.
These are the same mathemathical methods used in our
previous studies [10,11]. Results are presented as mean ±
SD for 21 periods during perphenazine treatment and 27
periods during risperidone treatment.
Sample entropy is a nonlinear measure, indicates the
degree of regularity (complexity) of time series, and is
the negative natural logarithm of an estimate of the con-
ditional probability that subseries of a certain length (m)
that match point-wise, within a tolerance (r), also match
at the next point. For the present study m = 2 and r = 0.2
were chosen.
SPSS version 15.0 was used for the statistical analyses.
Results
The results from the fMRI acquisition showed significant
activations during the mental arithmetic task when ana-
lyzed separately for the two sessions (using an uncor-
rected significance threshold of p < .001), in the occipital
lobe, right parietal lobule, and pre-central / SMA area,
and in an extended area in the pre-motor areas in the
frontal lobe (BA 4/6), and in the superior parietal lobule
(BA7). The parietal activation for the mental arithmetic
task would fit previous findings of parietal cortex activa-
tions for number calculations, in particular with a right-
sided laterality effect. Figure 2 shows the difference acti-
vation between session 1 (FGA) and 2 (SGA).
We also compared the activation in condition 2 (SGA)
and condition 1 (FGA), by subtracting the images for the
respective condition, using an uncorrected significance
threshold of p < .01 due to loss of degrees of freedom. This
showed remaining activations when subtracting images for
condition 2 from images for condition 1 in the right inferior
frontal/insula region, (BA 13) extending across the pre-
motor cortex, in the superior parietal lobule (BA 7) and in
the occipital lobe/lingual gyrus (BA 18). Increasing the sig-
nificance threshold to p < .001 did not yield any significantly
remaining effects for condition 1 compared to condition 2.
Results of the actigraph recordings are shown in
Table 1. Mean daytime motor activity was not changed
after switching of medication. The standard deviation
was slightly, but not significantly, lower with risperidone
than with perphenazine. The RMSSD however, was
significantly reduced after switching to risperidone, and
also the RMSSD/SD ratio.
Conclusions
This study showed that brain activation decreased in
areas critical for cognitive functioning, when a patient
with schizophrenia was changed from FGA to a SGA
medication. Total motor activity, however, was not al-
tered during this change in medication, although our
Figure 2 fMRI results.
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alters variability measures towards what was seen in a
healthy control group shown in one of our prior
studies [11].
We do not have test-retest data for fMRI from this
particular study. This may represent a limitation of the
study, since intra- and inter-individual variability gener-
ally is a problem in fMRI studies. However we do not
think that our findings are caused by such confounding
effects, since other studies, using variants of the same
paradigm have shown similar patterns as found after
medication in the present study [9,12]. An additional
limitation of the fMRI data is the possibility that some
of the changes from the first to the second session could
be driven by learning effects and by the instruction to
press the response button on target trials, which could
lead to reduced activation due to facilitation. This is
however not likely to explain all the findings that also
were outside of areas to be affected. Another limitation
is the rather weak statistical effects, not surviving stand-
ard correction procedures for multiple significance tests.
Such procedures are typically applied to group average
data, and may have reduced applicability for a single
case study.
A case study like the current study has its obvious lim-
itations when it comes to generalizations to the popula-
tion of schizophrenia patients. However, group averages
based on large samples could equally be criticised for
lacking in representativeness for a single patient, which
is what the clinician is facing. Group averages are by def-
inition not fully representative for any individual subjectTable 1 Results from actigraphic recordings (mean ± SD)
Perphenazin Risperidone
Mean activity 301 ± 79 298 ± 48
SD 270 ± 67 254 ± 43
RMSSD 250 ± 48 216 ± 19**
RMSSD/SD 0.94 ± 10 0.87 ± 12*
Sample entropy 1.35 ± 0.18 1.33 ± 0.29
* p <0.05 t-test.
** p <0.01 t-test.in the group, both because of the effect of statistical
averaging and from the perspective of individual vari-
ation in response to antipsychotic medication (which is
substantial in schizophrenia). Thus, reporting data for a
single patient, measured longitudinally, being his own
control, may yield clinically relevant data.
The patterns of variability in the motor activity after
switching antipsychotics from a FGA to a SGA are not
easy to interpret. While the mean motor activity level
and sample entropy were unchanged, risperidone re-
duced variability, particularly the variability from minute
to minute, reflected in the RMSSD and also the
RMSSD/SD ratio, towards what has been reported in
healthy controls [11]. Nonlinear methods have addressed
the severe disturbances in neurocognitive dysfunctioning
as one of the core features of schizophrenia [13,14].
Wrist worn actigraphy for motor registration and mag-
netic resonance imaging for brain activation have shown
correlations between motor activity and changes in brain
structure [15]. Our findings comparing a patient switching
from a first to a second generation antipsychotic supports
these findings.
The high perphenazine level observed in our patient
could be explained by the low CYP2D6 metabolic
capacity [16].
The decreased activation in the right inferior frontal and
insula region is somewhat of a puzzle since one would have
expected increased activation. It has been suggested that
the inferior frontal gyrus and anterior insula areas are in-
volved in complex attentional and working memory pro-
cessing. Possibly, these brain areas are involved in cognitive
control related to attentional focus on stimuli that are ur-
gent or close in time and space [17], and it is unclear how
such functions relate to reduced activation. Moreover, the
right fronto-insular cortex has been implicated in a wide
range of cognitive control mechanisms involved in a variety
of cognitive control processes, including conflict and error
monitoring, interference resolution, and response selection
[18]. The inferior frontal gyrus and anterior insula has also
been associated with psychosis. Insular dysfunction may be
important for the development of psychosis due to its influ-
ence on the salience network [19]. Furthermore, the right
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in auditory hallucinations [20].
We conclude that changes in neuronal brain activation
decreased in areas critical for cognitive functioning when
a patient with schizophrenia was changed from a FGA
to a SGA. At the same time although the total motor
activity was not altered, variability measures changed
towards values seen in healthy controls. Our study
underscores the value of casuistic reports of schizo-
phrenic patients examined during different conditions
using objective recording methods in pharmacological
treatment studies. Although the actigraph data were
partly in accordance with the hypothesis, the brain acti-
vation results were unexpected, and not hypothesized
and would need careful replication in a group study with
proper statistical power, before any firm conclusions can
be reached.
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